These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30529931)

  • 41. Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs.
    Viveiros M; Martins M; Rodrigues L; Machado D; Couto I; Ainsa J; Amaral L
    Expert Rev Anti Infect Ther; 2012 Sep; 10(9):983-98. PubMed ID: 23106274
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Contribution of putative efflux pump genes to isoniazid resistance in clinical isolates of
    Narang A; Giri A; Gupta S; Garima K; Bose M; Varma-Basil M
    Int J Mycobacteriol; 2017; 6(2):177-183. PubMed ID: 28559521
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mycobactin Analogues with Excellent Pharmacokinetic Profile Demonstrate Potent Antitubercular Specific Activity and Exceptional Efflux Pump Inhibition.
    Shyam M; Verma H; Bhattacharje G; Mukherjee P; Singh S; Kamilya S; Jalani P; Das S; Dasgupta A; Mondal A; Das AK; Singh A; Brucoli F; Bagnéris C; Dickman R; Basavanakatti VN; Naresh Babu P; Sankaran V; Dev A; Sinha BN; Bhakta S; Jayaprakash V
    J Med Chem; 2022 Jan; 65(1):234-256. PubMed ID: 34981940
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MmpS5/MmpL5 as an efflux pump in Mycobacterium species.
    Briffotaux J; Huang W; Wang X; Gicquel B
    Tuberculosis (Edinb); 2017 Dec; 107():13-19. PubMed ID: 29050760
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches.
    Villemagne B; Flipo M; Blondiaux N; Crauste C; Malaquin S; Leroux F; Piveteau C; Villeret V; Brodin P; Villoutreix BO; Sperandio O; Soror SH; Wohlkönig A; Wintjens R; Deprez B; Baulard AR; Willand N
    J Med Chem; 2014 Jun; 57(11):4876-88. PubMed ID: 24818704
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of novel coupled mutations in the katG gene (His276Met, Gln295His and Ser315Thr) in a multidrug-resistant Mycobacterium tuberculosis strain from Chennai, India, and insight into the molecular mechanism of isoniazid resistance using structural bioinformatics approaches.
    Ramasubban G; Therese KL; Vetrivel U; Sivashanmugam M; Rajan P; Sridhar R; Madhavan HN; Meenakshi N
    Int J Antimicrob Agents; 2011 Apr; 37(4):368-72. PubMed ID: 21330112
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis.
    Machado D; Pires D; Perdigão J; Couto I; Portugal I; Martins M; Amaral L; Anes E; Viveiros M
    PLoS One; 2016; 11(2):e0149326. PubMed ID: 26919135
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations.
    Saxena S; Abdullah M; Sriram D; Guruprasad L
    J Biomol Struct Dyn; 2018 Sep; 36(12):3184-3198. PubMed ID: 28948866
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Involvement of efflux pumps in the resistance to peptidoglycan synthesis inhibitors in Mycobacterium tuberculosis.
    Dinesh N; Sharma S; Balganesh M
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1941-3. PubMed ID: 23335736
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In silico high-throughput virtual screening and molecular dynamics simulation study to identify inhibitor for AdeABC efflux pump of Acinetobacter baumannii.
    Verma P; Tiwari M; Tiwari V
    J Biomol Struct Dyn; 2018 Apr; 36(5):1182-1194. PubMed ID: 28393677
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis.
    Gupta A; Pal SK; Pandey D; Fakir NA; Rathod S; Sinha D; SivaKumar S; Sinha P; Periera M; Balgam S; Sekar G; UmaDevi KR; Anupurba S; Nema V
    Ann Clin Microbiol Antimicrob; 2017 Aug; 16(1):56. PubMed ID: 28821299
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efflux pump gene expression in multidrug-resistant Mycobacterium tuberculosis clinical isolates.
    Li G; Zhang J; Guo Q; Jiang Y; Wei J; Zhao LL; Zhao X; Lu J; Wan K
    PLoS One; 2015; 10(2):e0119013. PubMed ID: 25695504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of potential proteasome inhibitors against
    Tyagi R; Srivastava M; Jain P; Pandey RP; Asthana S; Kumar D; Raj VS
    J Biomol Struct Dyn; 2022 Mar; 40(5):2189-2203. PubMed ID: 33074049
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of interactions of clinical mutants of catalase-peroxidase (KatG) responsible for isoniazid resistance in Mycobacterium tuberculosis with derivatives of isoniazid.
    Unissa AN; Doss C GP; Kumar T; Swathi S; Lakshmi AR; Hanna LE
    J Glob Antimicrob Resist; 2017 Dec; 11():57-67. PubMed ID: 28743650
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro combinatory activity of piperine and anti-tuberculosis drugs in Mycobacterium tuberculosis.
    Hegeto LA; Caleffi-Ferracioli KR; Nakamura-Vasconcelos SS; Almeida AL; Baldin VP; Nakamura CV; Siqueira VLD; Scodro RBL; Cardoso RF
    Tuberculosis (Edinb); 2018 Jul; 111():35-40. PubMed ID: 30029912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo.
    Vickers CF; Silva APG; Chakraborty A; Fernandez P; Kurepina N; Saville C; Naranjo Y; Pons M; Schnettger LS; Gutierrez MG; Park S; Kreiswith BN; Perlin DS; Thomas EJ; Cavet JS; Tabernero L
    J Med Chem; 2018 Sep; 61(18):8337-8352. PubMed ID: 30153005
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis.
    Aínsa JA; Blokpoel MC; Otal I; Young DB; De Smet KA; Martín C
    J Bacteriol; 1998 Nov; 180(22):5836-43. PubMed ID: 9811639
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of potent chemical antituberculosis agents targeting Mycobacterium tuberculosis acetohydroxyacid synthase.
    Jung IP; Ha NR; Lee SC; Ryoo SW; Yoon MY
    Int J Antimicrob Agents; 2016 Sep; 48(3):247-58. PubMed ID: 27451857
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis.
    Matviiuk T; Madacki J; Mori G; Orena BS; Menendez C; Kysil A; André-Barrès C; Rodriguez F; Korduláková J; Mallet-Ladeira S; Voitenko Z; Pasca MR; Lherbet C; Baltas M
    Eur J Med Chem; 2016 Nov; 123():462-475. PubMed ID: 27490025
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Detection of First-Line Drug Resistance Mutations and Drug-Protein Interaction Dynamics from Tuberculosis Patients in South India.
    Nachappa SA; Neelambike SM; Amruthavalli C; Ramachandra NB
    Microb Drug Resist; 2018 May; 24(4):377-385. PubMed ID: 28813625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.